Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million
Mandate

Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million

December 01, 2021 Capital Markets and Public M&A

Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will provide Cell Impact with gross issue proceeds of SEK 349 million

Cell Impact is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique scalable method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Anna Jonsson, Rikard Lindahl, Joel Magnusson and Lorin Arabi.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026